PMID: 8584757Oct 20, 1995Paper

Central administration of antisense oligodeoxynucleotides to neuropeptide Y (NPY) mRNA reveals the critical role of newly synthesized NPY in regulation of LHRH release

Regulatory Peptides
P S KalraS P Kalra

Abstract

Compelling evidence shows that the episodic and cyclic secretion of hypothalamic luteinizing hormone releasing hormone (LHRH), the primary stimulator of pituitary LH release, is subject to regulation by neuropeptide Y (NPY). We have reported earlier that sequential treatment of ovariectomized (ovx) rats with estrogen and progesterone to stimulate a preovulatory-type LH surge elevated the levels of both NPY and preproNPY mRNA levels in the hypothalamus concomitant with dynamic changes in LHRH activity. The present study was designed to determine whether these elevations in NPY content and gene expression represent new synthesis of NPY that is crucial to elicit LHRH discharge. Ovx, steroid-primed rats received intracerebroventricular injections of an unmodified 20-mer oligodeoxynucleotide (oligo) complementary to the NPY mRNA sequence. Control rats were injected similarly with either saline or the sense or missense oligos. Results showed that control rats displayed a characteristic surge-type elevation in plasma LH levels that was not affected by the administration of missense or sense oligos. However, in rats injected with the antisense oligo, the steroid-induced LH surge was completely blocked. In an additional experiment, NPY ...Continue Reading

References

Dec 2, 1976·Nature·D K SarkarN M Sherwood
Dec 1, 1991·Current Opinion in Biotechnology·S L Eck, G J Nabel
Jan 1, 1990·Scientific American·H M Weintraub
Apr 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J AllenG Heinrich
Oct 1, 1986·Physiology & Behavior·J P Kroon, A L Riley
Sep 10, 1984·Life Sciences·S P Kalra, W R Crowley
Jun 1, 1994·Plant Molecular Biology·C Z JiangS Rodermel
Feb 1, 1994·Trends in Pharmacological Sciences·C Wahlestedt

❮ Previous
Next ❯

Citations

Aug 2, 2012·Cellular and Molecular Life Sciences : CMLS·Carol F Elias, Darshana Purohit
Jul 25, 2003·Biochemical and Biophysical Research Communications·Christopher M MayerDenise D Belsham
Jul 20, 2002·Frontiers in Neuroendocrinology·M Susan Smith, Kevin L Grove
Nov 5, 1998·Regulatory Peptides·A KanataniM Ihara
Apr 5, 2001·Peptides·T L HorvathS P Kalra
Sep 1, 1997·Neurochemistry International·I Neumann
Feb 3, 1999·Annals of the New York Academy of Sciences·S P Kalra, T L Horvath
Jul 30, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Li-Ying Fu, Anthony N van den Pol
Sep 23, 2006·Frontiers in Neuroendocrinology·Carola EvaAlessandra Oberto
Aug 28, 1999·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·N A Silveira, C R Franci
Apr 7, 1999·Antisense & Nucleic Acid Drug Development·A W Szklarczyk, L Kaczmarek
Jan 21, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Prasad S DalviDenise D Belsham
Aug 5, 2020·Molecular and Cellular Endocrinology·Emma K McIlwraith, Denise D Belsham

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.